On vaccine efficacy and boosters

Thursday, 2 September 2021

Goldman with the note:

Outbreaks in economies that vaccinated early such as Israel and new studies have raised doubts about the durability of vaccine protection and prompted booster rollouts. How much has the efficacy of major Western vaccines waned over time and how much will boosters help?

We first show that lower recent estimates of vaccine efficacy against infections reflect a reduction in the immune response to vaccines over time, higher vaccine resistance of the Delta variant, but also biases in several real world studies.

The full text of this article is available to MacroBusiness subscribers

$1 for your first month, then:

$24.99 / month

$249 / year

Cancel at any time through our billing provider, Stripe

About the author

David Llewellyn-Smith is Chief Strategist at the MB Fund and MB Super. David is the founding publisher and editor of MacroBusiness and was the founding publisher and global economy editor of The Diplomat, the Asia Pacific’s leading geo-politics and economics portal. He is also a former gold trader and economic commentator at The Sydney Morning Herald, The Age, the ABC and Business Spectator. He is the co-author of The Great Crash of 2008 with Ross Garnaut and was the editor of the second Garnaut Climate Change Review.